Report in Brief
CHC can progress to liver cirrhosis, liver cancer, and premature death, and is the most common reason for liver transplantation.
There are six major genotypes of the hepatitis C virus. In North America, genotype 1 is the most common and the most difficult to treat. New direct-acting antiviral drugs are now being used to treat CHC genotype 1. One of these drugs, simeprevir, may be less effective in patients with a specific type of the hepatitis C virus: genotype 1a, with Q80K polymorphism.
This laboratory test analyzes the genetic sequence of the virus and reports on mutations.
In clinical trials, patients with the Q80K polymorphism were less likely to achieve SVR if they were treated with simeprevir (58%, versus 84% for those without Q80K polymorphism). The simeprevir manufacturer recommends that, when accessible, testing for Q80K polymorphism be considered in patients with CHC genotype 1a. Information on the diagnostic accuracy of such tests would help inform decision-making on the use of simeprevir.
- What is the accuracy of laboratory tests for the identification of Q80K polymorphism in patients with hepatitis C virus genotype 1?
No evidence regarding the diagnostic accuracy of laboratory tests for hepatitis C Q80K mutation was identified.
hepatitis c, hepatitis, polymorphism, genetic, laboratory tests, Polymorphism, Genetic